Table IV.
Univariate analysis of the prognostic factors for PFS and OS.
| Prognostic factors | Cases | PFS | OS |
|---|---|---|---|
| Gender | |||
| Male | 33 | ||
| Female | 22 | 0.293 | 0.613 |
| Age (years) | |||
| ≥55 | 31 | ||
| <55 | 24 | 0.008 | 0.025 |
| Genotype | |||
| IgA+IgD | 19 | ||
| Other | 36 | 0.250 | 0.574 |
| Bone destruction (sites) | |||
| ≥3 | 30 | ||
| <3 | 25 | 0.180 | 0.804 |
| Hb (g/l) | |||
| ≤85 | 30 | ||
| >85 | 25 | 0.215 | 0.354 |
| ALB (g/l) | |||
| ≤30 | 24 | ||
| >30 | 31 | 0.058 | 0.345 |
| Cr (μmol/l) | |||
| ≥177 | 12 | ||
| <177 | 43 | 0.366 | 0.702 |
| Ca (mmol/l) | |||
| ≥2.17 | 30 | ||
| <2.17 | 25 | 0.534 | 0.675 |
| LDH (U/l) | |||
| ≥200 | 28 | ||
| <200 | 27 | 0.434 | 0.435 |
| β2-MG (mg/l) | |||
| ≥5 | 30 | ||
| <5 | 25 | 0.116 | 0.167 |
| ISS stage | |||
| III | 27 | ||
| I+II | 28 | 0.121 | 0.247 |
| DS stage | |||
| III | 44 | ||
| I+III | 11 | 0.437 | 0.294 |
| Proportion of plasma cells (%) | |||
| ≥30 | 28 | ||
| <30 | 27 | 0.797 | 0.942 |
| Chromosome | |||
| Abnormal | 8 | ||
| Normal | 47 | 0.318 | 0.736 |
| Induction chemotherapy | |||
| Traditional | 21 | ||
| Bortezomib | 34 | 0.136 | 0.578 |
| Efficacy of induction chemotherapy | |||
| Without CR | 37 | ||
| With CR | 18 | 0.087 | 0.262 |
| ASCT | 27 | ||
| Efficacy of induction chemotherapy | |||
| Non-ASCT | 28 | 0.048 | 0.373 |
| Maintenance treatment | |||
| No | 20 | ||
| Yes | 35 | 0.143 | 0.012 |
| Overall treatment | |||
| No | 41 | ||
| Yes | 14 | 0.010 | 0.106 |
PFS, progression free survival; OS, overall survival; CR, complete remission; ASCT, autologous hematopoietic stem cell; Hb, hemoautologous hematopoietic stem cell; Hb, hemoglobin; ALB, albumin; Cr, creatine; Ca, blood calcium; LDH, lactate dehydrogenase; β2-MG, β2-microglobulin; ISS, International Staging System; DS, Durie-Salmon Staging System.